These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 15467441)

  • 1. Cell cycle effects and induction of premitotic apoptosis by irofulven in synchronized cancer cells.
    Woynarowski JM; Woynarowska BA; Trevino AV; Salinas R; Herman TS; Waters SJ; Macdonald JR
    Cancer Biol Ther; 2004 Nov; 3(11):1137-42; discussion 1143-4. PubMed ID: 15467441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irofulven: resurgence for alkylating therapy in cancer?
    Dent P; Grant S
    Cancer Biol Ther; 2004 Nov; 3(11):1143-4. PubMed ID: 15640616
    [No Abstract]   [Full Text] [Related]  

  • 3. Apoptosis induction by the dual-action DNA- and protein-reactive antitumor drug irofulven is largely Bcl-2-independent.
    Herzig MC; Trevino AV; Liang H; Salinas R; Waters SJ; MacDonald JR; Woynarowska BA; Woynarowski JM
    Biochem Pharmacol; 2003 Feb; 65(4):503-13. PubMed ID: 12566077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Caspase-mediated apoptosis and caspase-independent cell death induced by irofulven in prostate cancer cells.
    Liang H; Salinas RA; Leal BZ; Kosakowska-Cholody T; Michejda CJ; Waters SJ; Herman TS; Woynarowski JM; Woynarowska BA
    Mol Cancer Ther; 2004 Nov; 3(11):1385-96. PubMed ID: 15542777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irofulven induces replication-dependent CHK2 activation related to p53 status.
    Wang Y; Wiltshire T; Senft J; Reed E; Wang W
    Biochem Pharmacol; 2007 Feb; 73(4):469-80. PubMed ID: 17118344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irofulven (6-hydroxymethylacylfulvene, MGI 114)-induced apoptosis in human pancreatic cancer cells is mediated by ERK and JNK kinases.
    Wang W; Waters SJ; MacDonald JR; Roth C; Shentu S; Freeman J; Von Hoff DD; Miller AR
    Anticancer Res; 2002; 22(2A):559-64. PubMed ID: 12014623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irofulven (6-hydroxymethylacylfulvene, MGI 114) induces caspase 8 and 9-mediated apoptosis in human pancreatic adenocarcinoma cells.
    Wang W; Waters SJ; MacDonald JR; Von Hoff DD; Strodel WE; Miller AR
    Anticancer Res; 2001; 21(3B):1789-94. PubMed ID: 11497260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irofulven induces apoptosis in breast cancer cells regardless of caspase-3 status.
    Herzig MC; Liang H; Johnson AE; Woynarowska B; Woynarowski JM
    Breast Cancer Res Treat; 2002 Jan; 71(2):133-43. PubMed ID: 11883439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model.
    Kelner MJ; McMorris TC; Rojas RJ; Estes LA; Suthipinijtham P
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):19-26. PubMed ID: 18305940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
    Serova M; Calvo F; Lokiec F; Koeppel F; Poindessous V; Larsen AK; Laar ES; Waters SJ; Cvitkovic E; Raymond E
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fanconi anemia D2 protein confers chemoresistance in response to the anticancer agent, irofulven.
    Wang Y; Wiltshire T; Senft J; Wenger SL; Reed E; Wang W
    Mol Cancer Ther; 2006 Dec; 5(12):3153-61. PubMed ID: 17172419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA1 contributes to cell cycle arrest and chemoresistance in response to the anticancer agent irofulven.
    Wiltshire T; Senft J; Wang Y; Konat GW; Wenger SL; Reed E; Wang W
    Mol Pharmacol; 2007 Apr; 71(4):1051-60. PubMed ID: 17229870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxyurea derivatives of irofulven with improved antitumor efficacy.
    Staake MD; Kashinatham A; McMorris TC; Estes LA; Kelner MJ
    Bioorg Med Chem Lett; 2016 Apr; 26(7):1836-8. PubMed ID: 26922141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of irofulven against human ovarian cancer cell lines, human tumor colony-forming units, and xenografts.
    van Laar ES; Izbicka E; Weitman S; Medina-Gundrum L; Macdonald JR; Waters SJ
    Int J Gynecol Cancer; 2004; 14(5):824-31. PubMed ID: 15361190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I clinical and pharmacokinetic trial of irofulven.
    Thomas JP; Arzoomanian R; Alberti D; Feierabend C; Binger K; Tutsch KD; Steele T; Marnocha R; Smith C; Smith S; MacDonald J; Wilding G; Bailey H
    Cancer Chemother Pharmacol; 2001 Dec; 48(6):467-72. PubMed ID: 11800027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models.
    Van Laar ES; Weitman S; MacDonald JR; Waters SJ
    Prostate; 2004 Apr; 59(1):22-32. PubMed ID: 14991863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in prostate-specific antigen (PSA) level correlate with growth inhibition of prostate cancer cells treated in vitro with a novel anticancer drug, irofulven.
    Woynarowska BAHigdon AL; Muñoz RM; Bushong P; Waters SJ
    Invest New Drugs; 2001; 19(4):283-91. PubMed ID: 11561687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Marked activity of irofulven toward human carcinoma cells: comparison with cisplatin and ecteinascidin.
    Poindessous V; Koeppel F; Raymond E; Comisso M; Waters SJ; Larsen AK
    Clin Cancer Res; 2003 Jul; 9(7):2817-25. PubMed ID: 12855662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NADPH alkenal/one oxidoreductase activity determines sensitivity of cancer cells to the chemotherapeutic alkylating agent irofulven.
    Dick RA; Yu X; Kensler TW
    Clin Cancer Res; 2004 Feb; 10(4):1492-9. PubMed ID: 14977853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-surface exposure of phosphatidylserine correlates with the stage of fludarabine-induced apoptosis in chronic lymphocytic leukemia and expression of apoptosis-regulating genes.
    Clodi K; Kliche KO; Zhao S; Weidner D; Schenk T; Consoli U; Jiang S; Snell V; Andreeff M
    Cytometry; 2000 May; 40(1):19-25. PubMed ID: 10754513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.